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Background: Ciguatoxins (CTXs) are polyether marine neurotoxins found in multiple reef-fish species and are
potent activators of voltage-gated sodium channels. It is estimated that up to 500,000 people annually experience
acute ciguatera poisoning from consuming toxic fish and a small percentage of these victims will develop a chronic,
multisymptom, multisystem illness, which can last years, termed a Chronic Inflammatory Response Syndrome (CIRS).
Symptoms of ciguatera CIRS include fatigue, cognitive deficits, neurologic deficits, pain and sensitivity to light. There
are few treatment options for ciguatera CIRS since little is known about its pathophysiology.
Methods: This study characterizes the transcriptional profile in whole blood of 11 patients with ciguatera-induced CIRS
and 11 normal controls run in duplicate using Agilent one color whole genome microarrays. Differential expression
was determined by using a combination of moderated t-test p-value and fold change (FC). Significant genes were
subjected to gene ontology, principal component analysis and SVM classification. Seven significant genes found by
microarray were validated by PCR.
Results: Using a low stringency (p < 0.05 and FC > 1.4) and a high stringency (p < 0.01 and FC > 1.5) filter, the resulting
gene sets of 185 and 55, respectively, showed clear separation of cases and controls by PCA as well as 100%
classification accuracy by SVM, indicating that the gene profiles can separate patients from controls. PCR results of 7
genes showed a 95% correlation to microarray data. Several genes identified by microarray are important in wound
healing (CD9, CD36, vWF and Factor XIII), adaptive immunity (HLA-DQB1, DQB2, IL18R1 and IL5RA) and innate
immunity (GZMK, TOLLIP, SIGIRR and VIPR2), overlapping several areas shown to be disrupted in a mouse model of
acute exposure to ciguatoxin. Another area of interest was differential expression of long, non-coding sequences, or
lncRNA.
Conclusions: Disruptions of innate and adaptive immune mechanisms were recorded at both the genomic and
proteomic level. A disruption in the HLA-T cell receptor axis could indicate HLA haplotype sensitivity for this chronic
syndrome, as noted in many autoimmune conditions. Taken together, these indicators of illness provide additional
insights into pathophysiology and potential therapies.
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Ciguatera fish poisoning (CFP) is the most common
marine toxin poisoning worldwide, with estimates of
50,000-500,000 cases annually [1]. Precise numbers of
cases are nearly impossible to obtain due to widespread
underreporting and the fact that no clinical diagnostic
test exists to verify the acute illness, which may result
from fish contaminated with as little as 0.1 ppb cigua-
toxin [2]. Produced in tropical and subtropical oceans by
benthic dinoflagellates of the genus Gambierdiscus,
ciguatoxins (CTXs) are found in numerous reef fish spe-
cies, such as barracuda, grouper and snapper, with larger
and older fish usually being the most toxic. As reviewed
by Lewis [3], families of ciguatoxins have been isolated
from the Pacific and Indian Oceans, along with the
Caribbean Sea, and suites of CTX congeners have been
distinguished by minor differences in their cyclic poly-
ether backbone and different toxicities. These heat
stable, lipid soluble, cyclic polyether toxins are potent
activators of voltage-gated sodium channels, and the
consumption of toxic levels is characterized by acute
gastrointestinal and neurological symptoms, including
vomiting, diarrhea, abdominal pain, headache, tachycar-
dia, prostration, severe localized itching, tingling of
extremities and lips, and temperature reversal [4]. While
most of these symptoms are self-healing in a matter of
weeks, other symptoms of CFP can last several years [2].
These long term symptoms can include fatigue, pain,
weakness, depression and cognitive deficits, as well as
hypersensitivity to inflammagen exposure [5].
Ciguatoxin is slowly metabolized in mammals after
ingestion. In rats, the plasma terminal half life was esti-
mated to be 82 and 112 hours after oral and intraperito-
neal administration, respectively, with the main route of
excretion through the feces [6]. While there are few
treatment options for CFP, most symptoms subside after
a few weeks, similar to the expected clearance of toxin.
Herbal remedies and the osmolyte mannitol have shown
limited efficacy if administered in an appropriate time
window [7,8]. It is still unknown why a small percentage
of acute poisonings, roughly 5%, transition into a
chronic illness characterized by a persistent inflamma-
tory syndrome. This syndrome, Chronic Inflammatory
Response Syndrome (CIRS), can be identified by serum
protein abnormalities in transforming growth factor
beta-1 (TGFβ-1), split product of complement compo-
nent 4 (C4a), vasoactive intestinal peptide (VIP) and
others [5].
Transcriptomic studies of acute CTX exposure were con-
ducted in mice with the most potent congener, P-CTX-1,
and followed the toxicogenomic effects over a 24 hour
period [9-11]. These studies examined three different organ
systems in parallel, the immune system using whole
blood, the central nervous system using the brain, anddetoxification mechanisms using the liver. Although the
mouse model system only studied the acute response,
and was confounded by a pronounced hypothermic re-
sponse to the toxin, some of the molecular pathways
that were disrupted were similar to those in patients
with ciguatera-induced CIRS, or CIRS-ciguatera, includ-
ing genes for complement and hemostasis. In mice, over
half of the 15 differentially expressed genes shared by all
three tissues had functions directly involving the immune
system, such as cytokines, interleukins and immunoglobu-
lin related genes [10]. Additionally, expression of inflam-
matory cytokines was shown in a murine macrophage cell
line upon direct exposure to P-CTX-1B [12].
There is neither a treatment nor a test for acute cigua-
toxin exposure, yet the effects are often debilitating and
on rare occasions, even deadly. Use of a CIRS treatment
protocol shows promise in chronic cases [5]. Although
proteomic abnormalities are documented in patients
with CIRS-ciguatera, it is relatively difficult to measure
protein expression on a global scale and the future
discovery of proteomic abnormalities may be slow. Mean-
while, advances in genomics technology make surveying
the expression of the genome fairly routine. We have evi-
dence that the immune system plays a role in responding
to this toxic exposure, as seen in both humans and mice
[5,11]. To gain an understanding of CIRS-ciguatera, this
study uses a top down approach, looking globally at im-
mune perturbations through gene expression and finding
elements implicated in pathophysiology. By focusing on
global gene expression in the blood, we hope to broaden
our understanding of dysfunctional systems, and encour-
age a focus on the proteomic discovery of biomarkers and
guideposts for treatment protocols in these patients.
Methods
Subjects
Participation in this study was voluntary and informed
consent was obtained from case and control subjects to
use their data for research purposes. Institutional Review
Board (IRB) approval for this study was granted by
Copernicus Group IRB, LLC, Research Triangle Park,
NC. Medical history and symptoms registries were re-
corded for cases and controls, as described in detail
previously [5]. Patient samples came from two separate
medical clinics and were considered as potential CIRS-
ciguatera cases (N = 11) if they were considered to have
(1) developed an acute illness typical of ciguatera within
24 hours of reef fish consumption (typical symptoms can
be found in [4,13]), (2) no confounding illnesses and (3)
symptoms that persisted beyond six months. Acquisition
of illness data as well as patient symptoms over the course
of illness can be found in Additional file 1: Tables S1
and Additional file 2: Table S2. Age matched volunteers
(N = 11) served as normal controls if they had no (1)
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(2) history of acute multisystem illness following fish
consumption, or multisystem, multisymptom illness fol-
lowing exposure to environmentally produced biotoxins
or (3) untreated chronic illness. Patients meeting initial
inclusion criteria received a physical examination, prote-
omic and transcriptomic blood analyses.
Serum protein labs
All patients reported in this work met the same case def-
inition for CIRS-ciguatera as described previously in a
larger proteomic study [5]. Nine of the eleven patients in
the current study were part of the former study, with
two new patients added here. Proteomic methods are
presented only to disclose parameters for positive diag-
nosis. For results of proteomics, please refer to [5]. The
diagnosis of CIRS-ciguatera was made using the standard
process of differential diagnosis, including the assessment
of exposure risks, symptoms and blood lab results that in-
cluded abnormalities in serum protein markers. Briefly,
patients must have presented with abnormal results in at
least four of the eight objective serum markers found most
informative for CIRS, which are TGFβ1, VIP, MSH,
MMP9, C4a, VEGF, ACTH/cortisol and ADH/osmolality.
Laboratory blood tests were performed by CLIA-licensed
facilities, LabCorp, Quest Diagnostics, National Jewish
Center (Denver) and Cambridge Biomedical. Testing in-
cluded alpha melanocyte stimulating hormone (MSH),
VIP, matrix metalloproteinase 9 (MMP9), split products of
complement component 3 (C3a) and C4a, TGFβ-1, vas-
cular endothelial growth factor (VEGF), lipid profile,
complete blood count (CBC), comprehensive metabolic
panel (CMP), gamma-glutamyl transpeptidase (GGTP),
thyroid stimulating hormone (TSH), lipid profile, and von
Willebrand’s profile. Patients with scores either < 50 or >
150 IU were classified as abnormal for von Willebrand’s
antigen. Dysregulation of simultaneously measured adre-
nocorticotropic hormone (ACTH)/cortisol and antidiure-
tic hormone (ADH)/osmolality was determined by (i)
absolute high (ACTH> 45 or cortisol > 21; ADH > 13 or
osmolality > 300) or low (ACTH < 5 or cortisol < 4;
ADH < 1.3 or osmolality < 275) values; or (ii) ACTH was
below 10 when cortisol was below 7; or ADH was below
2.2 when osmolality was 292–300 for the two-paired
tests; or (iii) ACTH was > 15 when cortisol was > 16;
and ADH > 4.0 when osmolality was 275–278 for the
two-paired tests.
RNA collection, extraction and labeling
Venous blood was drawn from the arms of subjects
into PAXgene RNA blood collection tubes (http://
www.preanalytix.com/product-catalog/blood/rna/products/
paxgene-blood-rna-tube/), incubated for six hours at room
temperature, then frozen at −80°C until RNA extractionswere performed. Total RNA was extracted with the
Qiagen PAXgene Blood miRNA System kit according
to manufacturer’s protocol. The total RNA was analyzed
using an Agilent 2100 bioanalyzer for RNA integrity (only
using samples with RIN scores ≥ 8) and was then quanti-
fied using a NanoDrop ND-1000 (Wilmington, DE).
Fluorescent labeling of RNA was performed according
to the manufacturer’s instructions for the Agilent Quick
Amp labeling kit. Total RNA (100 ng) was amplified and
labeled with Cy3 dye. This amplification product was
measured for quantity and dye incorporation using the
Nanodrop ND-1000 and then hybridized to Agilent cata-
logue Human Whole Genome V2 microarrays.
Microarray hybridizations and scanning
All microarray hybridizations were performed according
to the manufacturer’s instructions in the One-Color
Microarray-Based Gene Expression Analysis manuals
with only one modification. Instead of hybridizing the
recommended amount of 1.6 μg Cy-3 labelled RNA to
the array, we used 2.4 μg to boost the signal because the
hemoglobin RNA removal step was not employed (this
increase was used only after careful analysis of its repro-
ducibility and results as compared with the standard
protocol). The fluorescently labelled RNA was hybrid-
ized to the microarray at 65 °C in a rotating oven. After
17 hours, the arrays were washed consecutively in solu-
tions of 6X SSPE with 0.005% N-lauroylsarcosine and
0.06X SSPE with 0.005% N-lauroylsarcosine for 1 min
each at room temperature. This wash was followed by a
final 15 s wash in acetonitrile. Microarrays were then
imaged on an Agilent microarray scanner and extracted
using Agilent Feature Extraction 9.5.
Microarray analysis
All scan data were imported into GeneSpring Multi-Omic
analysis software version 12.6.1 and normalized using the
default parameter of the 75th percentile shift. Probes were
first filtered by intensity, only keeping ones with a mini-
mum of 40 counts in at least 50% of samples that consti-
tuted either the patient or control class. Probe intensity
values for each class were averaged and subjected to a
moderated t-test. By using the moderated t-test p value
(p) and patient vs control fold change (FC) cut-offs, two
gene lists of interest were then generated with different
levels of stringency. The low stringency (LS) gene set
contained probes with a p < 0.05 and a FC > 1.4, while
the high stringency gene set (HS) contained probes with
a p < 0.01 and FC > 1.5. Each gene set was subjected to
gene ontology (GO) and KEGG molecular pathway ana-
lysis to identify the possible enrichment of genes with
specific biological themes using the web tool Database
for Annotation, Visualization and Integrated Discovery
(DAVID) 6.7.
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profiles individually, and second by averaging the repli-
cate arrays for each subject, with the averaged replicate
data results reported in Supplementary material. Gene
set data were subjected to Principal Component Analysis
(PCA) as well as classification algorithms, such as
Support Vector Machines (SVM), within the GeneSpring
environment to determine if differences in gene expression
could be used to stratify patient from control samples.
qPCR
Eight genes selected from the array data were analyzed by
quantitative real-time PCR (qPCR) in seven patients and
seven controls (these subjects were selected based on
quantity of RNA remaining after microarrays). Sequences
of hydatidiform mole associated and imprinted (non-pro-
tein coding) (HYMAI, access number: NR_002768), von
Willebrand factor (VWF, NM_000552), coagulation factor
XIII, A1 polypeptide (F13A1, NM_000129), interleukin 18
receptor accessory protein (IL18RAP, NM_003853) and T
cell receptor beta variable 28 (TCRb28, AB305916) were
selected for primer design using PrimerQuest (https://
www.idtdna.com/Scitools/Applications/Primerquest/).
Primers for CD9 molecule (CD9), chromosome X open
reading frame 65 (CXorf65) and coiled-coil domain
containing 12 (CCDC12) were selected from PrimerBank
(http://pga.mgh.harvard.edu/primerbank/). CCDC12 was
used a reference gene as its expression was unchanged
and stable for the subjects in this cohort. Primers were
synthesized by Integrated DNA Technologies (Coralville,
IA) and specificities were verified by BLASTN analysis
against all GenBank entries. Relative levels of mRNA were
determined using qPCR on an ABI7000 (Applied Biosys-
tems). Optimized qPCR parameters for each gene were
determined using pooled cDNA (1:10 diluted), reverse
transcribed from 1200 ng of total RNA from two control
subjects with a high capacity RNA-to-cDNA Kit (Applied
Biosystems, Foster, CA) according to manufacturer’s in-
structions. Reactions were performed in a volume of 20 μl
with primer concentration of 300 nM, 10 μl SYBR Green
Master Mix (Applied Biosystems) and 2 μl 1:10 diluted
cDNA. At the end of each real-time PCR reaction, PCR
products were subjected to a melt curve analysis. Negative
controls (minus reverse transcriptase) were run for each
gene to confirm the absence of contaminating DNA.
Amplification efficiencies (E) were estimated from a six-
point standard curve, ranging from 1:10 to 1:5000 dilu-
tion, for each gene using the formula E = 10-1/slope-1
[14] resulting in a correlation coefficient R2 > 99.4% and
E = 0.976–1.045. All samples and negative controls were
reverse transcribed in duplicate. qPCR for each gene
was then run in duplicate from each duplicate RT for a
total of four values for each subject/gene pair. These
four Ct values for each subject/gene were averaged andthen normalized to the corresponding measured mRNA Ct
value of the reference gene CCDC12, which did not show
significant variation across samples in microarray hybrid-
izations. Comparative Ct method of analysis (2-ΔΔCt) was
used to determine changes in gene expression between
patients and normal controls.
Results
Microarray
All microarray data have been uploaded to NCBI’s Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo/, GEO series accession number GSE58625) for inde-
pendent analysis. Each array passed all quality control
standards as recommended by the manufacturer, Agilent
Technologies. Duplicate (technical replicate) whole gen-
ome microarrays for 11 patients (9 males and 2 females;
mean age 51.4, SD 6.1) and 11 controls (9 males and 2 fe-
males; mean age 50.7, SD 7.8), for a total of 44 arrays,
were uploaded to GeneSpring. The arrays were divided
into patient and control classes, and the probes were fil-
tered for signal intensities of greater than 40 in at least
50% of the samples in one of the two classes. This reduced
the number of experimental probes from 34,183 to
19,495. The data were then subjected to a moderated
t-test and filtered by p-values and FCs to produce two
gene sets, LS and HS. The LS filtering resulted in 182
significant probes (Additional file 3: Table S3) while
the HS filtering resulted in 55 probes (Table 1). The
FC cut-off is considered the best indicator of true dif-
ferential gene expression [15,16] and qPCR validation
of Agilent microarray results at a minimum threshold
of 1.4 FC has been robust at this specific genomic core
[17]. Most differential gene expression remained under a
2 fold change, although the little studied sialic acid-
binding immunoglobulin-type lectin, SIGLEC14 exhibited
by far the greatest degree of change at 7.5 FC. However,
that large change was due to the fact that 3 of the 11 con-
trols expressed the gene at undetectable levels, while all
patients had detectable levels of expression.
The LS and HS gene sets were subjected to gene
ontology analysis using both GeneSpring and the web
tool DAVID 6.7 [18]. Although no significant results
were generated after Benjamini multiple test corrections
were applied, the top hits in the biological process
category were (1) wound healing with an uncorrected
p-value of 0.00016 (corrected p = 0.0899), (2) platelet
alpha granule with an uncorrected p-value of 0.00069
(corrected p = 0.109) and (4) coagulation with an uncor-
rected p-value of .0044 (corrected p = 0.359). The genes
CD9, CD36, VWF and Factor XIII were included in all
three categories.
To determine the power of the experiment, an online
calculator at the U. of Texas MD Anderson bioinfor-
matics website (http://bioinformatics.mdanderson.org/
Table 1 HS gene list
p value FC GeneSymbol Description Genbank Acc
3.36E-04 1.56 ATHL1 Acid trehalase-like 1 NM_025092
5.53E-03 -1.61 APCDD1 Adenomatosis polyposis coli down-regulated 1 NM_153000
2.02E-04 1.63 AEBP1 AE binding protein 1 NM_001129
1.47E-03 1.52 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 NM_000927
2.91E-05 1.62 CELSR3 Cadherin, EGF LAG seven-pass G-type receptor 3 NM_001407
1.34E-03 1.62 CD274 CD274 molecule (CD274), transcript variant 1 NM_014143
7.44E-05 -1.56 CD36 CD36 molecule (thrombospondin receptor) NM_001001547
4.01E-04 -1.90 CD9 CD9 molecule NM_001769
9.33E-05 1.51 LOC100289090 cDNA FLJ33063 fis, clone TRACH2000047 AK057625
3.24E-04 1.60 LOC692247 cDNA FLJ36520 fis, clone TRACH2002100 AK093839
4.36E-03 1.51 C17orf66 Chromosome 17 open reading frame 66 NM_152781
4.00E-06 1.81 C6orf163 Chromosome 6 open reading frame 163 NM_001010868
7.42E-04 -1.68 CYB5R2 Cytochrome b5 reductase 2 NM_016229
1.33E-03 2.16 DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 NM_018665
7.91E-03 1.76 EIF4G3 Eukaryotic translation initiation factor 4 gamma 3 NC_018912.2
3.33E-07 1.51 N/A Formin-like 1 protein (Leukocyte formin) AC_000149.1
4.71E-04 1.67 GPR125 G protein-coupled receptor 125 NM_145290
8.75E-03 1.79 GATA2 GATA binding protein 2 (GATA2), transcript variant 1 NM_001145661
5.97E-03 1.54 GZMK Granzyme K (granzyme 3; tryptase II) NM_002104
3.89E-04 1.51 GBP5 Guanylate binding protein 5 variant 1 NM_052942
1.74E-03 1.53 LRRC37A4P Hypothetical protein LOC652203 BC107850
1.01E-03 -3.85 ITGB2 Integrin beta chain, beta 2 variant (Fragment) NC_018932.2
5.33E-03 -1.69 IL5RA Interleukin 5 receptor, alpha, variant 3 NM_175725
1.75E-03 1.66 NEAT1 lncRNA Nuclear paraspeckle assembly transcript 1 AF001893
6.55E-04 1.55 LINC00282 lncRNA 282 (LINC00282) NR_027047
1.08E-04 1.58 HYMAI lncRNA Hydatidiform mole associated and imprinted NR_002768
3.66E-04 1.74 LMF1 lncRNA Lipase maturation factor 1 variant 4 NR_036442
3.62E-05 -1.89 N/A lncRNA TCONS_l2_00011463 NC_018928
4.20E-03 -1.73 LYPD2 LY6/PLAUR domain containing 2 NM_205545
4.37E-03 -1.63 MARCO Macrophage receptor with collagenous structure NM_006770
1.85E-03 -2.43 N/A Major histocompatibility complex, class I, V (pseudogene) NC_018917
2.95E-03 -1.61 HLA-DQB1 MHC class II, DQ beta 1 variant 1 NM_002123
6.20E-03 -2.16 HLA-DQB1 MHC class II, DQ beta 1 variant 2 NM_001243961
8.09E-04 -1.54 HLA-DQB1 MHC class II, DQ beta 1 variant 3 NM_001243962
2.96E-04 -2.13 PADI6 Peptidyl arginine deiminase, type VI NM_207421
4.12E-05 -2.26 PEX6 Peroxisomal biogenesis factor 6 NM_000287
3.69E-04 -1.82 PEX6 Peroxisomal biogenesis factor 6 NM_000287
9.37E-03 1.55 PDE4DIP Phosphodiesterase 4D interacting protein variant 1 NM_014644
3.56E-03 1.80 PLGLB1 Plasminogen-like B1 BC022294
2.19E-03 1.51 LOC345051 Predicted: hCG38984 variant X1 XR_109844
3.22E-03 -1.74 PPP1R17 Protein phosphatase 1, regulatory subunit 17 variant 1 NM_006658
8.37E-03 -1.67 PDK4 Pyruvate dehydrogenase kinase, isozyme 4 NM_002612
2.41E-04 -1.51 ARHGAP22 Rho GTPase activating protein 22, variant 3 NM_021226
8.34E-04 1.52 ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 AK090448
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6.37E-03 7.57 SIGLEC14 Sialic acid binding Ig-like lectin 14 NM_001098612
8.88E-06 1.55 SIGIRR Single immunoglobulin and toll-interleukin 1 receptor XM_005253044
1.58E-04 1.53 TCRBV27 T cell receptor beta variable 27 AB305921
1.22E-03 2.02 TCRBV28 T cell receptor beta variable 28 AY751906
1.55E-03 2.34 TCRBV28 T cell receptor beta variable 28 AB305916
3.33E-04 1.51 TCRBV6 T cell receptor beta variable 6-4 A25966
6.60E-03 -1.77 TOLLIP Toll interacting protein NM_019009
3.79E-03 3.03 TUBB2A Tubulin, beta 2A class Iia NM_001069
1.36E-03 1.55 VIPR2 Vasoactive intestinal peptide receptor 2 NM_003382
3.82E-03 -1.71 VWF von Willebrand factor NM_000552
8.82E-03 2.74 ZFP57 ZFP57 zinc finger protein NM_001109809
Genes that exhibited a FC > 1.5 and p < 0.01 in patients v controls. Bold shading indicates PCR analysis, italics indicates genes with the highest loading factors in
PCA analysis. Genes sorted by description.
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size of 11 is small, the estimated power of the experi-
ment was found to be 0.6, meaning that only an esti-
mated 60% of true differentially expressed genes will
be identified. In an effort to further validate genes of
interest, we compared the 11 patients to a wider con-
trol database run on the same platform. This larger
control data set was made up of 79 gene expression
profiles from 30 male and 18 female control subjects
between the ages of 25 and 65 (48.7 mean). Additional
file 4: Figure S1 shows 21 box whisker plots of genes of
interests found throughout the discussion.
PCR
All PCR primer pairs (Additional file 5: Table S4) were
optimized to produce single band products when run on
the Agilent Bioanalzyer 2100. Average Cts for all sub-
jects in this cohort were as follows, VWF = 28.19,
HYMAI = 27.8, CXorf65 = 25.9, CD9 = 25.4, TCRb28 =
24.3, F13A1 = 23.6, IL18RAP = 23.5 and the reference
gene CCDC12 = 24.5.
The PCR results were strongly supportive of the
microarray data (Figure 1) with a Pearson correlation
coefficient of 0.955 (p = 0.00076) across the seven genes
analyzed. When the Ct values for patients and controls
were compared by s-test, significant differences were
shown for HYMAI (p = 0.03), CD9 (p = 0.006), CXorf65
(p = 0.05), IL18RAP (p = 0.005) and TCRb28 (p = 0.02).
However, no significant differences were found be-
tween controls and patients for VWF (p = 0.40) and
F13A1 (p = 0.87) as the PCR results, although corrob-
orating the down-regulation of both genes in patients,
showed a smaller change than the microarray.
PCA plot and SVM classification
Using the HS and LS gene sets, a PCA was performed,
and an SVM classification algorithm was run inside theGeneSpring environment. The PCA plot produced a
clear separation between control and patient samples
(Figure 2 and Additional file 6: Figure S2). However, the
smaller HS set provided a tighter grouping of samples.
Genes with the highest loading factors were TCRBV27,
SIGIRR, CESLR3, cDNA FLJ33063 and formin like pro-
tein, and are highlighted in Table 1. It was typical that
the top and bottom 10 values of the 44 total data profiles
were exclusively controls and cases, respectively, for
each of these genes. For example, of the 44 normalized
values for the gene SIGIRR (up in patients 1.7 fold), the
lowest 8 values were all control with the 9th lowest being
a patient, while the 12 highest values were patients with
the 13th highest being a control.
Using a polynomial kernel and a “leave one out” train-
ing method, an SVM classification algorithm was built
by further removing 2 randomly selected male control
and patient data. Eight profiles from 4 subjects (i.e., both
replicates) were removed from the pool, leaving 36 out
of 44 data profiles for training. The algorithm correctly
classified patient and control samples with 100% accur-
acy during training for both the HS and LS gene sets.
When the prediction model was run using all 44 profiles
it still correctly predicted the classes of all the samples
for both averaged and individual replicates. Table 2 (and
Additional file 7: Table S5) shows the results of analysis
with the HS data set, and although three of the four
unknown sample predictions were of the lowest confi-
dence for the entire group, one of the unknown samples
showed a classification confidence of nearly 100%.
Discussion
Although many important genes may remain undetected
or overlooked, we have endeavored to highlight several
pathways, as well as individual genes, that likely contrib-
ute to CIRS-ciguatera using data predominantly from







































Figure 1 PCR validation of microarray. PCR results were compared with microarray data. Pearson correlation between the two methods was
0.955, with a p = 0.00076.
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Previous functional genomics studies in mice have
shown disruption in the complement and coagulation
pathways after an acute exposure to ciguatoxin [9].
Additionally, human cases of CIRS-ciguatera have been
identified with similar abnormalities, such as elevated
complement C4a, irregularities in VWF and Factor
VIII, and elevated levels of plasminogen activator
inhibitor-1 [5]. The HS gene set identified in the
current study contains VWF, coagulation factor XIII,
thrombospondin (CD36) and CD9. These genes func-
tion in platelet activation, which was one of the most
enriched pathways revealed by DAVID GO analysis.
CD9 is a member of the tetraspanin family and one of
the most abundant proteins on the platelet cell mem-
brane [19]. It was determined to be down-regulated
here by microarray (1.9 fold) and validated by qPCR
(1.8 fold), and it has long been known to play a role in
cell motility and adhesion [20]. An interesting aspect
of CD9 in the case of CIRS-ciguatera is that it influences
the expression of MMP9, which is found up-regulated
at the protein level in the plasma of over 60% of CIRS-
ciguatera cases. In keratinocytes, down-regulation of
CD9 was found to increase activity and expression of
MMP9 through JNK signaling [20], while in a fibrosar-
coma cell line, epithelial growth factor receptor, EGFR,was an important intermediary for increased release of
pro-MMP9 by CD9 [21]. CD9 is critical for platelet
microparticle release, which are formed from budding
of the cytoplasmic membrane and are an order of mag-
nitude larger than exosomes [19]. Roughly 70–90% of
all microparticles in the bloodstream originate from
platelets [22]. They are thought to be part of a wide-
ranging form of inter-cellular communication that func-
tion by carrying bioactive components and signaling
molecules, which can be released into target cells, in
many instances, altering the function of those cells [22].
In addition to their function in coagulation, the micro-
particles are also implicated in a range of inflammatory
and autoimmune diseases [22,23]. A recent study identi-
fied another high density platelet receptor, CD36 (aka,
thrombospondin receptor), which was similarly down-
regulated in these CIRS-ciguatera patients (1.56 fold),
that strongly co-localized with CD9, not only on the
surface of platelets, but also on dermal microvessel
endothelial cells, possibly forming sites for platelet ad-
hesion and aggregation [24]. These receptors, together
with the genes for VWF and Factor XIII, which were
also down-regulated in this study, most likely play a role
in the coagulopathies and hemodynamics associated
with CIRS-ciguatera. What is also interesting is that one







Figure 2 PCA plot. Control and patient profiles were subjected to principal component analysis and rotated to angles that visually
best exhibit their separation. X, Y and Z axes indicate first three principle components. HS = high stringency, LS = low stringency
gene sets.
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relies on hemorrhaging of an incision in the tail of the
fish to indicate toxicity [25].
Long non-coding RNA (lnc-RNA)
Several lncRNAs were found to be differentially expressed
in this study, leading us to believe that these regulators of
transcription and translation play an important role in
CIRS-ciguatera. Non-coding RNA (ncRNA) research is a
relatively new field and, although microRNA research far
outpaces lncRNA, its importance is becoming noteworthy
as some single lncRNA knockouts have proven lethal in
mice [26]. Relatively little is known about the functions
of most lncRNAs; however, a few species have been
characterized because of the significance of their func-
tions. One such species was found to be up-regulated
1.66 fold in CIRS-ciguatera patients, Nuclear Enriched
Abundant Transcript 1, NEAT1. NEAT1 is a critical
component of nuclear paraspeckles, a nuclear body foundto have a role in sequestering certain RNA transcripts in
the nucleoplasm, thus keeping them from being translated
into proteins in the cytoplasm. It is thought that this com-
plex binds transcripts through their edited 3′ UTR that is
then cleaved under a stress response, which allows the
transcripts to be sent immediately to the cytoplasm for
translation [27]. In a different paradigm of transcriptional
control, up-regulation of NEAT1 was described in re-
sponse to viral infection and Toll receptor pathways,
which in turn led to increased binding and sequestration
of IL-8 transcriptional repressors by the paraspeckle, thus
allowing increased expression of the cytokine [28]. Early
work identified a smaller form of NEAT1 in trophoblasts
that could suppress gene expression of the major histo-
compatability complex (MHC) through sequestration of a
critical transcription factor, signal transducer and activator
of transcription 1 (STAT1), although in this instance,
STAT1 was sequestered in the cytoplasm instead of the
nucleus [29]. This fetal isoform of NEAT1 was not found
Table 2 SVM classification
Identifier Gender Trained Predicted Confidence
Control 1-1 Female Control Control 0.754
Control 1-2 Female Control Control 0.764
Control 2-1 Male Control Control 0.796
Control 2-2 Male Control Control 0.789
Control 3-1 Male Control Control 0.794
Control 3-2 Male Control Control 0.829
Control 4-1 Male Control Control 0.805
Control 4-2 Male Control Control 0.832
Control 5-1 Male Control Control 1.000
Control 5-2 Male Control Control 1.000
Control 6-1 Male Control Control 0.826
Control 6-2 Male Control Control 0.821
Control 7-1 Female Control Control 0.877
Control 7-2 Female Control Control 0.827
Control 8-1 Male Control Control 0.710
Control 8-2 Male Control Control 0.772
Control 9-1 Male Control Control 0.796
Control 9-2 Male Control Control 0.936
Patient 1-1 Male Patient Patient 0.819
Patient 1-2 Male Patient Patient 0.805
Patient 2-1 Male Patient Patient 0.858
Patient 2-2 Male Patient Patient 0.847
Patient 3-1 Male Patient Patient 0.858
Patient 3-2 Male Patient Patient 0.917
Patient 4-1 Female Patient Patient 0.858
Patient 4-2 Female Patient Patient 0.853
Patient 5-1 Male Patient Patient 0.844
Patient 5-2 Male Patient Patient 0.813
Patient 6-1 Male Patient Patient 0.929
Patient 6-2 Male Patient Patient 0.898
Patient 7-1 Male Patient Patient 0.763
Patient 7-2 Male Patient Patient 0.852
Patient 8-1 Male Patient Patient 0.790
Patient 8-2 Male Patient Patient 0.821
Patient 9-1 Female Patient Patient 0.847
Patient 9-2 Female Patient Patient 0.904
*Control 10-1 Male Control 0.449
*Control 10-2 Male Control 0.399
*Control 11-1 Male Control 0.627
*Control 11-2 Male Control 0.660
*Patient 10-1 Male Patient 0.019
*Patient 10-2 Male Patient 0.108
*Patient 11-1 Male Patient 0.976
*Patient 11-2 Male Patient 1.000
Results of predictions and confidence for cases of CIRS-ciguatera and controls using a Support Vector Machines classification algorithm, while withholding eight
random data profiles* from training.
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several MHC genes were significantly down-regulated in
our patient samples while STAT1 was significantly up-
regulated 1.42 fold.
MHC and adaptive immunity
Adaptive immunity involves the destruction of foreign
pathogens and presentation of their peptide remains to
T cells to begin the processes of antibody production by
B cells, and “attack on site” natural killer (NK) cells and
cytotoxic T cells. The direct killing of cells usually in-
volves the emptying of lytic enzymes, granzymes (GZM),
onto targeted cells. Until recently, it was thought that
these cells acted exclusively as part of the innate im-
mune response. However, new evidence has shown that
these cells also shape adaptive responses and can play a
role in autoimmune disorders, such as Multiple Sclerosis,
where CD56bright NK cells were shown to kill activated au-
tologous T cells through GZM-K (up-regulated 1.54 fold
here) dependent mechanisms. GZMK has also been
suggested as a marker for different stages of sepsis
[30]. The heterodimeric HLA-DQ protein, composed
of an alpha and beta subunit, acts as an antigen-
presenting molecule of foreign peptide fragments, as op-
posed to MHC class I proteins that present self molecules.
Several probes for the MHC class II gene HLA-DQB were
found down-regulated in CIRS-ciguatera patients. In earl-
ier work, we discovered that certain DRB and DQB class
II HLA haplotypes were more susceptible to chronic ill-
ness caused by acute exposure to ciguatoxins [5]. This is
not unusual in chronic inflammatory/autoimmune ill-
nesses. In fact, the greatest risk factor for Type I diabetes
in Caucasians and African Americans was found to be cer-
tain HLA-DQ genotypes [31], as was DRB-DQ genotypes
in late autoimmune diabetes in adults (LADA) [32].
Additionally, two DQ haplotypes are linked with nearly
all celiac disease (CD) [33], the DQ2 haplotype, which is
present in more than 95% of CD, and DQ8, which is
present in the remainder. These two haplotypes are also
over-represented in many other inflammatory disorders,
including Addison’s disease, Hashimotos thyroiditis,
Graves’ disease, Sjogren’s syndrome and others (for re-
view see [33]).
Antigen presenting cells (APC) display foreign peptide
fragments through MHC receptors, these fragments are
then probed by T cells through the T cell receptor
(TCR). The TCR is a heterodimer, typically composed of
alpha and beta subunits, with each subunit containing a
variable region that interacts with the APC presented
peptide. Out of a possible 46 TCR beta variable (TCRBV)
probes (coding for 45 genes), our LS set of 193 significant
probes contained six, all up-regulated from 1.51 to 2.33
FC. T cells not only combat infectious pathogens, they are
also important in the surveillance of autoreactive selfantigens that can result in autoimmune syndromes or can-
cer. The gene CD274, aka programmed cell death ligand 1
(PDL1, or B7-H1), up-regulated 1.7 fold here, is important
for maintaining peripheral tolerance and is a powerful
suppressor of T cell-mediated immunity. Over expression
of CD274 by tumors, or due to chronic infection allows
immune avoidance through T cell anergy, exhaustion,
apoptosis and other mechanisms, and high levels of the
receptor have been correlated with poor prognoses for
certain cancers [29]. The up-regulation of TCRs and
PDL1 seem to indicate an attempt to generate T cells
clones for a specific antigen.
Inflammation
Our findings are replete with genes involved in inflam-
mation, and although a simple explanation of how this
differential expression accounts for CIRS is impossible,
there are too many important inflammatory threads to
ignore. Activation of inflammation is well documented
through Toll-like receptors (TLR) and Interleukin-1 re-
ceptor like receptor (ILR) signaling. The single immuno-
globulin and IL-1 receptor (SIGIRR), found up-regulated
in our patients 1.55 fold, is implicated in infectious and
sterile inflammation, as well as autoimmune disease. It is
also known to blunt the signaling of both TLR and IL-1,
in addition to other interleukins such as IL-18 (for
review see [34]). The IL-18 receptor is an alpha-beta
heterodimer, and the beta subunit, IL-18RAP, was up-
regulated in patients 1.4 fold. This subunit is also part of
a linkage disequilibrium block found in CD, and its
mRNA expression in blood is an important disease cor-
relate [35]. VIP was shown to down-regulate TLRs while
at the same time up-regulating SIGIRR expression [36].
Since over 90% of CIRS-ciguatera patients have findings
of abnormally low VIP in plasma [5], the down-
regulation of the VIP receptor found here, VIPR2 (1.7
fold), would seemingly further diminish the anti-
inflammatory effects of what little neuropeptide is cir-
culating in the blood. Toll interacting protein (TOLLIP),
down-regulated in patients 1.77 fold, is an inhibitor of
TLR signaling and has also been shown to modulate
both IL-1 and LPS inflammatory pathways, as well as
TNFα and IL-6 gene expression [37]. Its role as an im-
mune regulator was further expanded when it was
found to inhibit TGFβ signaling [38], which could prove
important in CIRS-ciguatera because TGFβ-1 is abnor-
mally high in over 90% of cases.
Proteomics
Because ciguatoxins are toxic in minute amounts, their
detection in tainted fish or exposed patients is extremely
difficult, and the diagnosis of CFP relies predominantly
on symptoms following a fish meal. Abnormalities in
blood proteomic measurements of MSH, VIP, C4a,
Ryan et al. BMC Medical Genomics  (2015) 8:15 Page 11 of 12TGFβ-1, MMP9, ADH/osmolality, ACTH/cortisol and/
or VEGF are routinely found in the chronic syndrome,
but we do not know if these anomalies are detectable
at the acute stage. Additionally, these proteomic ab-
normalities are not unique to CFP, but are also found
in patients with other biotoxin-induced CIRS such as
toxic mold exposure [39] and acute Lyme disease [40].
The concept of a “final common pathway” of chronic
immune activation seen in these diverse syndromes is
consistent with the presentation of a multisystem illness
that is not defined by any single symptom or group of
symptoms, or unique proteome with our current testing.
This increases the importance of identifying a genomic
fingerprint for these different illnesses to provide objective
support for use in differential diagnosis. Additionally,
since the proteome of whole blood is not simply the prod-
uct of white blood cells, but is more so the product of all
the organs being supplied, there is no tidy explanation to
correlate gene expression with the proteomic abnormal-
ities we have recorded. However, the benefit of this para-
digm in whole blood is that while the genomic research
interrogates the leukocytes, the proteomics can interro-
gate the entire body. Further research is needed to clarify
this dichotomy of genomic responses in white cells
separately from the proteome of blood in inflammatory
illnesses.
Conclusions
Symptoms of the acute stage of ciguatera are easily ex-
plained by circulating toxin, but chronic illness is not.
We cannot say that all chronic illness after ciguatoxin
exposure results in a CIRS syndrome, but of the cases
we see, an immune disequilibrium after the acute trig-
ger is quite typical. The role of platelet microparticles
has not been defined in any of the CIRS illnesses to
date, but with growing evidence of their potential path-
ology and importance in communication and direction
of immune functions, we will include their study going
forward. Dysregulation of the HLA/T-cell receptor axis
seen here reminds us of autoimmune elements seen in
other inflammatory illnesses, such as CD. With suscep-
tible HLA haplotypes recorded previously in CIRS-
ciguatera, also similar to CD, as well as IgGs reactive
to gliadins, gluten produced inflammation could be an
important contributor to a protracted recovery in these
patients, as could many other inflammagens imposing
on a hyper-active immune system. By elucidating the
roles of environmental triggers and predisposing genetic
backgrounds, the etiology of inflammatory illnesses is be-
coming more transparent. Now, with several innate and
adaptive inflammatory genes to investigate further, we feel
that genomic testing will serve an expanded clinical role
as work proceeds on defining the parameters of acute ci-
guatera and CIRS.Additional files
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